New drug combo may tame immunotherapy skin rash without hurting cancer fight
NCT ID NCT07530224
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests JAK inhibitors (upadacitinib or tofacitinib) in 35 adults with solid tumors who have severe skin rashes from immunotherapy that didn't improve with steroids. The goal is to see if these pills can quickly relieve the rash and itching while allowing patients to keep receiving their cancer treatment. The study will also monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JAK inhibitors (upadacitinib or tofacitinib)
What this could lead to
If it works, this could offer a new way to treat severe skin rashes caused by immunotherapy, allowing patients to continue their cancer treatment without needing steroids.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply to everyone. JAK inhibitors also have risks like infection or blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Quzhou people's hospital
Quzhou, Zhejiang, 324000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••